MacroGenics to Participate in Upcoming Investor Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
MacroGenics (MGNX) PT Raised to $24 at BTIG, 'Discussions with Physicians Increase our Confidence in Vobra Duo’s Profile'
March 4, 2024 5:02 AM ESTBTIG analyst Kaveri Pohlman raised the price target on MacroGenics (NASDAQ: MGNX) to $24.00 (from $12.00) while maintaining a Buy rating.
The analyst comments "We are increasing our PT to $24 from $12 based on our recent conversations with KOLs who remain excited about vobra duos potential in prostate cancer. Our KOL interactions suggest that the data... More



